MX2024006589A - Formulaciones de vacunas contra el coronavirus. - Google Patents

Formulaciones de vacunas contra el coronavirus.

Info

Publication number
MX2024006589A
MX2024006589A MX2024006589A MX2024006589A MX2024006589A MX 2024006589 A MX2024006589 A MX 2024006589A MX 2024006589 A MX2024006589 A MX 2024006589A MX 2024006589 A MX2024006589 A MX 2024006589A MX 2024006589 A MX2024006589 A MX 2024006589A
Authority
MX
Mexico
Prior art keywords
nanoparticles
vaccine formulations
coronavirus vaccine
vaccines
disclosed
Prior art date
Application number
MX2024006589A
Other languages
English (en)
Spanish (es)
Inventor
Gale Smith
Michael J Massare
Jing-Hui Tian
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of MX2024006589A publication Critical patent/MX2024006589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024006589A 2021-11-30 2022-11-30 Formulaciones de vacunas contra el coronavirus. MX2024006589A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163284497P 2021-11-30 2021-11-30
US202163292120P 2021-12-21 2021-12-21
US202163293519P 2021-12-23 2021-12-23
US202263332530P 2022-04-19 2022-04-19
US202263367678P 2022-07-05 2022-07-05
PCT/US2022/080700 WO2023102448A2 (en) 2021-11-30 2022-11-30 Coronavirus vaccine formulations

Publications (1)

Publication Number Publication Date
MX2024006589A true MX2024006589A (es) 2024-08-20

Family

ID=86613115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006589A MX2024006589A (es) 2021-11-30 2022-11-30 Formulaciones de vacunas contra el coronavirus.

Country Status (10)

Country Link
US (1) US20250025549A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440613A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024545420A (cg-RX-API-DMAC7.html)
KR (1) KR20240125935A (cg-RX-API-DMAC7.html)
AU (1) AU2022399829A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241118A1 (cg-RX-API-DMAC7.html)
IL (1) IL313254A (cg-RX-API-DMAC7.html)
MX (1) MX2024006589A (cg-RX-API-DMAC7.html)
TW (1) TW202332685A (cg-RX-API-DMAC7.html)
WO (1) WO2023102448A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN116622651A (zh) * 2022-03-25 2023-08-22 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 缺失Furin酶切位点的新冠病毒株及其应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024089638A1 (en) * 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
US20250144200A1 (en) 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021214064A1 (en) * 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
WO2021154763A1 (en) * 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
TW202204380A (zh) * 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
JP2025500433A (ja) * 2021-12-23 2025-01-09 ノババックス,インコーポレイテッド 抗SARS-CoV-2スパイク(S)抗体およびCOVID-19の処置におけるそれらの使用
IL318555A (en) * 2022-07-26 2025-03-01 Novavax Inc ACE2 Blockade Test to Assess the Immunogenicity of Vaccines
US20260028644A1 (en) * 2022-07-26 2026-01-29 Novavax, Inc. Pseudovirus based neutralization assay for evaluating vaccine immunogenicity

Also Published As

Publication number Publication date
EP4440613A4 (en) 2026-02-11
WO2023102448A3 (en) 2023-08-31
EP4440613A2 (en) 2024-10-09
KR20240125935A (ko) 2024-08-20
US20250025549A1 (en) 2025-01-23
JP2024545420A (ja) 2024-12-06
AU2022399829A1 (en) 2024-06-27
IL313254A (en) 2024-08-01
WO2023102448A2 (en) 2023-06-08
CA3241118A1 (en) 2023-06-08
TW202332685A (zh) 2023-08-16

Similar Documents

Publication Publication Date Title
ZA202401922B (en) Coronavirus vaccine formulations
WO2023102448A3 (en) Coronavirus vaccine formulations
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
MX2023011163A (es) Formulaciones para vacuna contra coronavirus.
CR10559A (es) Vacuna de influenza
WO2010019262A3 (en) Polyvalent vaccine
TW200722101A (en) Novel composition
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
WO2007024941A3 (en) Polyvalent vaccine
FI4023249T3 (fi) Nukleiinihapporokotteita
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX2021004478A (es) Dispositivo hiperbarico y metodos para producir vacunas inactivadas y para replegar/solubilizar proteinas recombinantes.
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
MX391930B (es) Vacuna contra la fiebre aftosa.
PH12018500305B1 (en) Multivalent vlp conjugates
MX2025012626A (es) Composiciones de vacuna sars-cov-2
ATE416788T1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
MX2023011129A (es) Mutantes del virus de la influenza b y usos de los mismos.
AR121151A1 (es) Formulaciones para vacuna contra coronavirus
ECSP14023407A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
MX2025009053A (es) Formulaciones de vacunas contra el vrs f